Management of mi
I'll start by reading the medical library skill, then search for MI management content in parallel.
Reading File
Now I'll run parallel searches across the library for MI management.
Finding Sources
Finding Sources
Searching PubMed
"myocardial infarction"[MeSH Terms] AND "management"[MeSH Terms]
Let me try broader searches:
Finding Sources
Finding Sources
Searching PubMed
"myocardial infarction"[MeSH Terms] AND "therapy"[MeSH Terms]
Excellent! Found great sources. Let me read the key clinical management sections from Braunwald's Heart Disease and Goldman-Cecil Medicine in parallel:
Reading File
Reading File
The block offsets didn't align well. Let me search directly for MI management paragraphs and the correct Goldman-Cecil MI section:
Finding Sources
Finding Sources
Now let me read the most clinically rich sections - Washington Manual ACS management and Morgan & Mikhail STEMI treatment:
Reading File
Reading File
Excellent data from Washington Manual. Let me get the rest of that section (reperfusion, post-MI care) and also search for NSTEMI management and complications:
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive data to compose a thorough, well-structured answer on MI management. Let me deliver it:
Management of Myocardial Infarction (MI)
MI management is divided into STEMI (ST-elevation MI) and NSTEMI/UA (non-ST-elevation MI/unstable angina) pathways, with additional considerations for peri-infarct care and secondary prevention.
1. Initial Assessment (First 10 Minutes)
- 12-lead ECG within 10 minutes of arrival - mandatory
- Serial ECGs if initial ECG is non-diagnostic but symptoms persist (may reveal evolving STEMI)
- Continuous telemetry for arrhythmia monitoring
- Targeted clinical exam
- Supplemental O₂ only if SpO₂ < 90% (routine O₂ is no longer recommended)
- Activate acute MI protocol in ED
2. Upstream Medical Therapy (Applies to All ACS)
Start immediately while preparing for reperfusion:
Antiplatelet Agents
| Drug | Dose | Notes |
|---|---|---|
| Aspirin (ASA) | 162-325 mg (chewed/crushed) | Non-enteric coated for rapid absorption |
| Clopidogrel | 600 mg loading, then 75-150 mg/d | 600 mg LD preferred; caution in elderly |
| Prasugrel | 60 mg loading, then 10 mg/d | More potent than clopidogrel; avoid if age >75, weight <60 kg, or prior stroke/TIA |
| Ticagrelor | 180 mg loading, then 90 mg BID | Mortality benefit over clopidogrel; limit ASA to ≤100 mg |
| Cangrelor | 30 µg/kg IV bolus, then 4 µg/kg/min | IV P2Y12 inhibitor; FDA-approved for PCI only |
Anticoagulants
| Drug | Dose | Notes |
|---|---|---|
| UFH | 60 units/kg IV bolus, then 12 units/kg/h | For all PCI patients and most thrombolytic recipients |
| Enoxaparin (LMWH) | 30 mg IV bolus + 1 mg/kg SC q12h | Alternative to UFH |
| Bivalirudin | Used in PCI | Direct thrombin inhibitor |
- Washington Manual of Medical Therapeutics, Table 4-17
3. STEMI-Specific Management - Reperfusion
The primary goal is rapid reperfusion. Time = myocardium.
Primary PCI (Preferred)
- Gold standard for STEMI reperfusion
- Goal: door-to-balloon time ≤90 minutes at a PCI-capable center
- AHA/ACC guidelines mandate PCI within 90 minutes of presentation
- Preferred over thrombolytics when achievable within the time window
Thrombolysis (If PCI Not Available in Time)
- Used when PCI cannot be performed within 90-120 minutes
- Administer within 12 hours of symptom onset
- Fibrin-selective agents are preferred:
| Agent | Dose |
|---|---|
| Alteplase (rt-PA) | 15 mg IV bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg over 60 min |
| Reteplase (r-PA) | 10 units IV bolus × 2, 30 minutes apart |
| Tenecteplase (TNK-tPA) | 0.5 mg/kg IV single bolus (30-50 mg total) |
Combine fibrinolytics with: ASA + clopidogrel + anticoagulant (UFH). GPIIb/IIIa inhibitors should NOT be combined.
Signs of successful thrombolysis:
- Relief of chest pain
-
50% reduction in ST elevations at 90 minutes
- Reperfusion arrhythmia (e.g., accelerated idioventricular rhythm)
Post-fibrinolysis: Routine coronary angiography within 24 hours reduces adverse events. All patients should get DAPT + ≥48 hours of anticoagulation.
Absolute Contraindications to Thrombolytics
- Prior intracranial hemorrhage
- Ischemic stroke within 3 months
- Known intracranial structural lesion (AVM, aneurysm, tumor)
- Closed head injury within 3 months
- Aortic dissection
- Severe uncontrolled hypertension (SBP >180, DBP >110 mmHg)
- Active bleeding or bleeding diathesis
- Acute pericarditis
Emergency CABG
Reserved for: severe left main disease, refractory ischemia with failed PCI, anatomy unsuitable for PCI, or acute mechanical complications (papillary muscle rupture, VSD, free wall rupture).
4. NSTEMI / Unstable Angina Management
- No fibrinolytic therapy (contraindicated in ST-depression pattern)
- Risk stratify using TIMI or GRACE risk scores
- Early invasive strategy (angiography within 24-48 h) for high-risk features: elevated troponins, dynamic ECG changes, recurrent symptoms, hemodynamic instability
- Conservative strategy for low-risk patients
- Same antiplatelet and anticoagulation backbone as STEMI
5. Peri-Infarct Monitoring (CCU)
- All STEMI patients should be in CCU or ICU for at least 24 hours
- Continuous telemetry for ischemia and arrhythmias
- Daily assessment: chest pain, new HF symptoms, ECG
- Examine for new murmurs (VSD, MR due to papillary muscle rupture)
- Baseline echocardiogram: to assess EF, wall motion abnormalities, valvular lesions, and LV thrombus
- Cardiac pacing: AV block in anterior MI is often unstable with wide-QRS escape rhythms and ~80% mortality - requires temporary then permanent pacing; AV block in inferior MI is usually transient
6. Post-MI Medical Therapy (Secondary Prevention)
| Drug | Duration/Target | Notes |
|---|---|---|
| Aspirin 81 mg/d | Indefinitely | |
| P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor) | Minimum 12 months | Regardless of stent type (BMS or DES) |
| Beta-blocker | Indefinitely | Start within 24 hours; mortality benefit |
| ACE inhibitor | Start within 24 hours; continue long-term | Most benefit when EF <40%, large anterior MI, or prior MI |
| ARB | Substitute for ACE-I intolerance | |
| High-intensity statin | Indefinitely | Target LDL <70 mg/dL or ≥50% reduction; add PCSK9 inhibitor or ezetimibe if needed |
| Aldosterone antagonist (spironolactone/eplerenone) | Long-term | When LVEF <40% or diabetes; caution with hyperkalemia/renal impairment |
- Washington Manual of Medical Therapeutics
7. Special Situations
Right Ventricular MI (RVMI)
- Occurs with proximal RCA occlusion causing inferior STEMI
- Classic triad: hypotension + elevated JVP + clear lung fields
- Diagnosis: ST elevation in V1 or V4R (right-sided leads)
- Treatment: IV fluids (RV is preload-dependent) - avoid nitrates and diuretics
- If hypotension persists: dobutamine ± IABP; right-sided mechanical support if pharmacology fails
- Heart block with AV dyssynchrony: sequential AV pacing provides marked benefit
Mechanical Complications
- VSD, free wall rupture, papillary muscle rupture with acute MR - surgical emergencies
- Usually occur within days of MI
Cardiogenic Shock
- IABP, vasopressors (norepinephrine), inotropes (dobutamine)
- Urgent PCI/revascularization
- Mechanical circulatory support (Impella, ECMO) in refractory cases
8. Mnemonic - Immediate STEMI Management: MONABCH
Morphine (for pain, use cautiously) | Oxygen (if SpO₂ <90%) | Nitrates | Aspirin | Beta-blocker | Clopidogrel/P2Y12 | Heparin
Sources: Washington Manual of Medical Therapeutics; Barash's Clinical Anesthesia; Morgan & Mikhail's Clinical Anesthesiology; AHA/ACC Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.